Radiopharmaceuticals in oncology Book Section
| Authors: | Goos, J. A. C. M.; Keinänen, O.; Zeglis, B. M.; Lewis, J. S. |
| Editors: | Kilbourn, M. R.; Scott, P. J. H. |
| Article/Chapter Title: | Radiopharmaceuticals in oncology |
| Abstract: | This chapter discusses recent trends in the use of radiopharmaceuticals in oncology. The first report of the internal use of radionuclides for cancer therapy emerged in 1913, when Frederick Proescher used intravenous injections of soluble radium-223 salts for the treatment of patients with a variety of diseases, including uterine cancer and leukemia. Imaging agents with greater specificity for cancer biomarkers have been developed to fully address the clinical needs of staging patients and monitoring their response to treatment. The chapter briefly summarizes a few key features of positron emission tomography and single-photon emission computed tomography imaging and the radionuclides used for these modalities. It highlights several clinical trials from the last decade using endoradiotherapeutic probes labeled with alpha-, beta- or Auger electron-emitting radionuclides. The therapeutic efficacy of a radiopharmaceutical is dictated by its physical and biochemical characteristics. © 2021 John Wiley & Sons Ltd. |
| Keywords: | positron emission tomography; radiopharmaceuticals; oncology; cancer therapy; imaging agents; physical characteristics; radionuclides; biochemical characteristics |
| Book Title: | Handbook of Radiopharmaceuticals: Methodology and Applications. 2nd ed |
| ISBN: | 9781119500544 |
| Publisher: | Wiley Blackwell |
| Publication Place: | Hoboken, NJ |
| Date Published: | 2021-01-01 |
| Start Page: | 535 |
| End Page: | 570 |
| Language: | English |
| DOI: | 10.1002/9781119500575.ch18 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Book chapter: 18 -- This chapter can be found under "PART V: Major Applications of Radiopharmaceuticals" -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work